Estetrol

Generic Name
Estetrol
Brand Names
Nextstellis 28 Day
Drug Type
Small Molecule
Chemical Formula
C18H24O4
CAS Number
15183-37-6
Unique Ingredient Identifier
ENB39R14VF
Background

Naturally or synthetically produced steroid estrogens have a wide range of pharmaceutical uses ranging from hormonal contraception to the treatment of menopausal symptoms. Estetrol (E4) is a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and used for contraception. It is more potent and is safer than the synthetic estrogen ethinylestradiol (EE2) found in 97% of oral contraceptive pills, reducing the environmental accumulation of unwanted endocrine disrupting chemicals (EDCs) that often lead to harmful epigenetic effects.

On April 15 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals were granted FDA approval for the oral contraceptive Estelle/Nextstellis, a combination of drospirenone and estetrol. Estetrol is the first new estrogen introduced to the USA in over 50 years and is the first approved estetrol product in the world. The combination of drospirenone and estetrol offers a new choice with a favourable safety profile for women seeking contraceptive therapy. In Canada, Nextstellis was approved for use in March 2021; it was developed by Mithra and is marketed by Searchlight Pharma.

Indication

Estetrol is indicated in combination with drospirenone for the prevention of pregnancy.

Associated Conditions
-
Associated Therapies
Oral Contraceptives

Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.

Phase 2
Completed
Conditions
Interventions
First Posted Date
2017-12-05
Last Posted Date
2021-06-18
Lead Sponsor
Pantarhei Oncology B.V.
Target Recruit Count
63
Registration Number
NCT03361969
Locations
🇳🇱

CWZ, Nijmegen, Netherlands

🇳🇱

Antonius Ziekenhuis, Sneek, Netherlands

🇳🇱

Andros Men's Health Institutes, Arnhem, Gelderland, Netherlands

and more 3 locations

E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2016-07-15
Last Posted Date
2024-11-18
Lead Sponsor
Donesta Bioscience
Target Recruit Count
260
Registration Number
NCT02834312
Locations
🇧🇪

Donesta Bioscience BV, Liège, Belgium

Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-03-25
Last Posted Date
2019-02-15
Lead Sponsor
Estetra
Target Recruit Count
6
Registration Number
NCT02720224
Locations
🇬🇧

Quotient Clinical, Ruddington, Nottingham, United Kingdom

Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-03-24
Last Posted Date
2021-06-18
Lead Sponsor
Pantarhei Oncology B.V.
Target Recruit Count
12
Registration Number
NCT02718144
Locations
🇩🇪

Katholisches Klinikum Mainz, Mainz, Germany

🇩🇪

Universitatsmedizin Mainz, Mainz, Germany

Evaluation of Safety and Efficacy of Estetrol in Healthy Men

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-03-24
Last Posted Date
2017-02-09
Lead Sponsor
Pantarhei Oncology B.V.
Target Recruit Count
45
Registration Number
NCT02718378
Locations
🇳🇱

QPS Netherlands BV, Groningen, Netherlands

Feasibility Study Into the Contraceptive Effect of Estetrol

First Posted Date
2007-11-26
Last Posted Date
2012-05-07
Lead Sponsor
Pantarhei Bioscience
Target Recruit Count
52
Registration Number
NCT00563472
Locations
🇳🇱

Dinox, Groningen, Netherlands

Preoperative Estetrol in Breast Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-04-23
Last Posted Date
2012-07-02
Lead Sponsor
Pantarhei Bioscience
Target Recruit Count
30
Registration Number
NCT00464516
Locations
🇦🇹

University of Vienna, Vienna, Austria

Study to Evaluate 3 Dosages of Estetrol After 28 Days Administration in Healthy Postmenopausal Women

Phase 1
Completed
Conditions
First Posted Date
2005-09-13
Last Posted Date
2012-05-21
Lead Sponsor
Pantarhei Bioscience
Target Recruit Count
49
Registration Number
NCT00163033
Locations
🇳🇱

Kendle Clinical Pharmacology Unit, Utrecht, Netherlands

© Copyright 2024. All Rights Reserved by MedPath